Showing results (131-140 of 260) with videos related to

Sort By:
Pageof 26
The Journal of Antimicrobial Chemotherapy|February 10, 2026
Biliary pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of orthotopic liver transplant recipientsMilo Gatti, Matteo Rinaldi, Cristiana Laici, et al.
Drugs in Context|March 27, 2026
Evaluating oritavancin for Gram-positive infections: a systematic review of on-label and off-label useAlex Soriano, Carlo Tascini, Marco Falcone, et al.
Antimicrobial Agents and Chemotherapy|September 25, 2003
Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomyFederico Pea, Federica Pavan, Ennio Nascimben, et al.
International Journal of Antimicrobial Agents|December 26, 2016
Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?Federico Pea, Paola Della Siega, Piergiorgio Cojutti, et al.
Pharmaceutics|February 25, 2023
Measuring Creatinine Clearance Is the Most Accurate Way for Calculating the Proper Continuous Infusion Meropenem Dose for Empirical Treatment of Severe Gram-Negative Infections among Critically Ill PatientsCarla Troisi, Pier Giorgio Cojutti, Matteo Rinaldi, et al.
Pharmaceutics|August 23, 2020
Population Pharmacokinetics of Continuous-Infusion Meropenem in Febrile Neutropenic Patients with Hematologic Malignancies: Dosing Strategies for Optimizing Empirical Treatment against Enterobacterales and P. aeruginosaPier Giorgio Cojutti, Anna Candoni, Davide Lazzarotto, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|July 17, 2024
Effect of incremental tazobactam concentrations on the bactericidal activity of piperacillin against ESBL-producing enterobacterales clinical isolates causing bacteraemiaMarta Palombo, Milo Gatti, Benedetta Secci, et al.
The Journal of Antimicrobial Chemotherapy|December 21, 2002
Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infectionsMario Furlanut, Loris Brollo, Emilio Lugatti, et al.
British Journal of Clinical Pharmacology|July 6, 2018
Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignanciesPier Giorgio Cojutti, Anna Candoni, Davide Lazzarotto, et al.
Entropy (Basel, Switzerland)|June 26, 2025
Leveraging Neural ODEs for Population Pharmacokinetics of Dalbavancin in Sparse Clinical DataTommaso Giacometti, Ettore Rocchi, Pier Giorgio Cojutti, et al.
Pageof 26